Shares of Outlook Therapeutics OTLK have tumbled 66.5% in a week. The massive crash was observed after the FDA issued a third complete response letter (CRL) in late December, rejecting OTLK’s ...
Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.
Shares of Outlook Therapeutics OTLK tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet ...
Outlook Therapeutics Inc. (NASDAQ:OTLK) revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients. In the NORSE EIGHT trial, ...
SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired ...
Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.
Outlook Therapeutics was upgraded to "buy" from a previous investment rating of "neutral" by analysts at BTIG. The ratings firm also set a price target of $50 on the OTLK stock. "Based on the results ...
Outlook Therapeutics (NASDAQ:OTLK) just reported results for the third quarter of 2024. Outlook Therapeutics reported earnings per share of -83 cents. This was above the analyst estimate for EPS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results